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Suppressing nonsense—a surprising
function for 5-azacytidine
Ada Shao & Miles F Wilkinson
In this issue of EMBO Molecular Medicine,
Bhuvanagiri et al report on a chemical
means to convert molecular junk into gold.
They identify a chemical inhibitor of a
quality control pathway that is best known
for its ability to clear cells of rubbish, but
that in certain cases can be detrimental
because it eliminates “useful” garbage.
The chemical inhibitor identified by Bhuva-
nagiri et al perturbs Nonsense-Mediated
RNA Decay (NMD), a RNA surveillance
pathway that targets mRNAs harboring
premature termination codons (PTCs) for
degradation (Kervestin & Jacobson, 2012).
See also: M Bhuvanagiri et al (December
2014)
“A little nonsense now and then isrelished by the wisest men.”These words are from Roald
Dahl, a writer lauded for his stories that
veered toward the ridiculous, but who
managed to probe into the inner psyche of
children and adults alike. Likewise, biology
takes advantage of what would appear to be
junk. A duplicated gene copy that has deteri-
orated (a pseudogene) sometimes finds new
life as a regulator of gene expression. Non-
coding regions within coding genes (introns)
engender a variety of functions. Transpos-
able elements transform themselves over
evolutionary time from mediators of havoc
(which they invoke as they jump into and
destroy useful genomic loci) to bearers
of novel functions, including regulatory
elements for neighboring genes.
Bhuvanagiri et al (2014) have identified a
means to allow mutant genes containing
aberrant stop codons to become useful. Stop
codons are recognized by the translation
apparatus; normally this event leads to
termination of translation and release of the
encoded protein. However, when a stop
codon is in a premature context, this assem-
bles components of the NMD machinery in a
manner that recruits RNA degradation
enzymes to rapidly degrade the PTC-bearing
mRNA. A common means to generate in-
frame PTCs is nonsense and frameshift
mutations, the class of mutations responsible
for causing one-third of human genetic
disease cases (Holbrook et al, 2004). PTCs
are also generated by biosynthetic errors,
including aberrant alternative splicing and
incorporation of inappropriate nucleotides
during transcription. Thus, NMD is a major
pathway for reducing the level of aberrant
mRNAs. However, normal mRNAs can also
sometimes be degraded by NMD. This
occurs when a normal stop codon is in a
context that is recognized as “premature”,
such as when the stop codon is followed by
a long 30 untranslated region or an intron.
The ability of NMD to degrade such “endoge-
nous NMD substrates” is regulated and likely
to be of biological value (Karam et al, 2013).
When it comes to disease, NMD is a two-
edged sword. NMD is a weapon worth
having when it targets a mutant disease-
causing gene. PTCs lead to the generation of
truncated proteins, some of which have
dominant-negative activity that, for exam-
ple, antagonize the functional protein
expressed from the wild-type allele (Fig 1).
By rapidly degrading the mRNA encoding
such dominant-negative proteins, NMD
protects cells from their deleterious effects
and thereby reduces or eliminates the symp-
toms of disease. Classic examples of this are
b-thalassemia, von Willebrand disease, and
Marfan syndrome (Holbrook et al, 2004).
While it serves as a useful RNA surveil-
lance role in many circumstances, NMD can
instead have a negative impact on cells. For
example, if the gene mutation generates a
PTC-containing transcript that produces a
truncated protein retaining partial (or some-
times even complete) function, then degra-
dation of the transcript by NMD will be
counterproductive (Fig 1). In the presence of
NMD, less of the truncated functional
protein will be produced, which can exacer-
bate disease symptoms. An example is cystic
fibrosis patients who have severe disease
when the mutation leads to the generation
of a PTC-containing CFTR transcript encod-
ing a still functional protein that is degraded
by NMD (Holbrook et al, 2004). In such
cases, NMD is a sword that turns on the
bearer of the sword. Such patients would
benefit from reduced NMD activity.
Currently known molecules that suppress
NMD activity fall into one of the five
following categories: NMD factor inhibitors,
translation inhibitors, suppressor tRNAs,
translation read-through inhibitors, and
Ca2+ release inducers. Examples of the first
class are wortmannin, caffeine, pateamine
A, and NMDI-1, which inhibit different NMD
components, including UPF1, SMG1, SMG7,
and eiF4A3 (Keeling & Bedwell, 2011;
Martin et al, 2014). Translation inhibitors
suppress NMD because the recognition of
the PTC depends on translation. Indeed, all
known translation inhibitors block NMD,
including cycloheximide, puromycin, aniso-
mycin, and even viruses (Carter et al, 1995).
Suppressor tRNAs repress NMD because
they instruct the translation apparatus to
interpret a stop codon as an amino acid-
encoding codon, thereby suppressing trans-
lation termination. Likewise, read-through
inhibitors increase the frequency at which
ribosomes misinterpret stop codons, causing
the ribosome to continue translation past
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the stop codon. Examples of read-through
inhibitors include aminoglycosides (e.g., the
antibiotics G418 and gentamycin) and the
small molecule, PTC-124 (Keeling &
Bedwell 2011). The final class of known
NMD inhibitors is those that elevate intracel-
lular Ca2+ levels (Nickless et al, 2014). Such
inhibitors include the cardiac glycosides,
ouabain, and digoxin. How increasing intra-
cellular Ca2+ levels suppresses NMD is
unknown.
Bhuvanagiri et al (2014) have identified a
new NMD inhibitor to add to this arsenal:
5-azacytidine (5AzaC). This was a surprising
finding, as 5AzaC is best known for its effects
on DNA, not RNA. 5AzaC is a cytidine
analogue that incorporates into DNA and
inhibits DNA methyltransferases. Because
5AzaC blocks DNA methylation, cells treated
with 5AzaC acquire hypomethylated DNA,
leading to activation of genes previously
suppressed by methylation, such as tumor
suppressor genes. Given this activity, 5AzaC
is used for the treatment of certain cancers; it
has also proved to be effective for treating
myelodysplastic syndrome patients. Bhuva-
nagiri et al (2014) identified 5AzaC in a
screen to identify small molecules that could
be rapidly applied in a therapeutic setting.
Thus, they screened a library of drugs that
had already been clinically licensed or were
in advanced clinical development. Using a
cell line expressing an NMD reporter, they
screened 1,120 such clinically licensed drugs
and identified several that inhibited NMD.
One of these compounds—5AzaC—held up
as a potent and specific NMD inhibitor at
clinically relevant/therapeutic doses. Other
hits identified in the screen, as well as chemi-
cal analogues of 5AzaC, either were only
effective at doses too high for clinical use or
had no effect on NMD.
Having found that 5AzaC is a potent
NMD inhibitor, as judged by its effect on the
levels of both an NMD reporter and endoge-
nous NMD substrates, Bhuvanagiri et al
(2014) next sought to determine the underly-
ing mechanism of its action. They observed
that 5AzaC increased the steady-state level
of mature mRNA but not pre-mRNA from
the NMD reporter, demonstrating that
5AzaC acts post-transcriptionally, as
expected for a NMD inhibitor. They then
tested various obvious mechanisms by
which 5AzaC might inhibit NMD. Unfortu-
nately, none of the mechanisms they tested
were measurably affected by 5AzaC; it
neither reduced the expression of known
NMD factors, nor did it inhibit translational
read-through or protein synthesis. Bhuvanagiri
et al (2014) then elected to investigate the
underlying mechanism using a proteomic
approach. Using global mass spectropho-
tometry analyses, they found that 5AzaC
upregulated 857 proteins and downregulated
1,002 proteins. One of the most strongly
upregulated proteins was the oncoprotein,
C-MYC. To test its causal role, the authors
asked whether preventing C-MYC upregula-
tion prevented 5AzaC’s ability to inhibit
NMD. Indeed, they found that C-MYC
knockdown (to pre-treatment level) comple-
tely eliminated the anti-NMD activity of
5AzaC. This provided strong evidence that
5AzaC acts through C-MYC to inhibit NMD.
Given that C-MYC is often overexpressed in
tumors, one might expect that some tumors
exhibit repressed NMD, which indeed has
been shown to be the case (Wang et al,
2011b; Liu et al, 2014). Furthermore, it was
previously shown that C-MYC overexpres-
sion is responsible for inhibiting NMD in
tumors (Wang et al, 2011a).
The findings of Bhuvanagiri et al (2014)
lead to an exciting new potential means to
treat genetic diseases caused by mutant
genes with nonsense or frameshift mutations
that encode functional proteins. Because
5AzaC is already FDA approved and has
been shown to have manageable side
effects, it can potentially be rapidly
repurposed into use for treating such
“NMD-induced diseases”, such as Duchenne
muscular dystrophy and cystic fibrosis.
Indeed, 5AzaC is already approved for
treatment of chronic diseases at doses
that Bhuvanagiri et al (2014) found to effec-
tively inhibit NMD. This means there will
hopefully be few bureaucratic and clinical
safety roadblocks to test its efficacy in
patients.
While promising, there are also concerns
with using 5AzaC therapeutically to treat
genetic diseases. A potential one is that by
inhibiting NMD, 5AzaC will promote the
accumulation of PTC-containing transcripts
that can cause toxicity or even new disease
states. For example, by stabilizing PTC-
bearing mRNAs encoding oncoproteins or
dominant-negative tumor suppressors,
5AzaC therapy could promote the formation
of tumors (Wang et al, 2011b; Liu et al,
2014). Another concern derives from the fact
that NMD degrades not only aberrant
transcripts, but also a subset of normal
transcripts, some of which are important for
normal developmental processes (Hwang &
Maquat, 2011). While likely less of a
concern in adults, where most developmen-
tal pathways are considered to be quiescent,
treatment of children with an agent that
significantly disrupts normal developmental
processes could potentially be quite hazard-
ous. Because of these potentially adverse
consequences, the benefit-to-risk ratio of
using 5AzaC must be carefully evaluated on
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Figure 1. NMD inhibition therapy has the potential to improve the clinical outcome of a subset of
human genetic diseases.
In cases where transcripts harboring a premature termination codon (PTC) produce a protein detrimental to the
cell, NMD reduces the dominant-negative or toxic effects by targeting these transcripts for degradation. In
transcripts in which the position of the PTC allows for the generation of a still functional protein, NMD is
detrimental because it degrades the useful transcript. By reversing this decay, NMD inhibition therapy could
improve disease symptoms.
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a case-by-case basis. Nevertheless, this new
NMD inhibitor offers promise as a course of
treatment for patients suffering from the
many diseases in which NMD either aggra-
vates or produces a disease condition.
Unleashing a little nonsense may indeed
turn out to be a good thing.
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